- Home
- Supplements
- Melatonin
- Frequent Night Waking
Melatonin for Frequent Night Waking
Melatonin is the most-used sleep supplement but its evidence is strongest for falling asleep and shifting the body clock, not for staying asleep. Prolonged-release melatonin has legitimate trial support for sleep maintenance in people over 55, whose own production has declined. For the common 3am waking pattern, the higher-yield moves are cutting evening alcohol, screening for sleep apnoea and depression, and CBT for insomnia.
Overview
Verdict
Modest maintenance benefit with prolonged-release in older adults; weak for general night waking.
How It Works
Dosing & Protocol
Typical dose
- Recommended dose
- Prolonged-release 2 mg 1-2 hours before bed (over-55s); immediate-release is weaker for maintenance
- Expected timeframe
- 1-2 weeks to judge effect
Protocol
- form
- Immediate-release for sleep onset; prolonged-release is the formulation studied for sleep maintenance in adults over 55
- duration
- 4 weeks, then reassess; prolonged-release is licensed for up to 13 weeks
- co factor
- Timing matters more than dose. Pair with a dark bedroom and no bright screens after dosing, since light suppresses the effect. Evidence is mixed: melatonin shifts sleep timing reliably but reduces night waking only modestly.
- titration
- Increase to 2 mg prolonged-release only if 1 mg is ineffective after two weeks - higher is not better
- starting dose
- 0.5-1 mg taken 1-2 hours before the target bedtime
Evidence
What the studies say
Meta-analysis: melatonin for the treatment of primary sleep disorders
Ferracioli-Oda E, et al.
This meta-analysis demonstrates that melatonin decreases sleep onset latency, increases total sleep time and improves overall sleep quality.
Pharmacotherapies for sleep disturbances in dementia
McCleery J, et al.
From single studies, we found no difference between melatonin and placebo groups for sleep efficiency, time awake after sleep onset, or number of night-time awakenings.
Prolonged-release melatonin improves sleep quality and morning alertness in insomnia patients aged 55 years and older and has no withdrawal effects
Lemoine P, et al.
PR-melatonin is the first drug shown to significantly improve quality of sleep and morning alertness in primary insomnia patients aged 55 years and older.
The effect of magnesium supplementation on primary insomnia in elderly: a double-blind placebo-controlled clinical trial
Abbasi B, Kimiagar M, Sadeghniiat K +3 more
Magnesium significantly increased sleep time and sleep efficiency and reduced Insomnia Severity Index scores, sleep onset latency and early morning awakening compared with placebo. Serum renin and melatonin increased and serum cortisol decreased in the magnesium group.
Safety
Caveats
Product dose accuracy is poor in some markets; start low. Morning drowsiness signals too high a dose or too-late dosing. It does not treat sleep apnoea, alcohol-driven fragmentation or depression-related early waking.
Less likely to help if
Medical Disclaimer
The information provided on this website is for educational and informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any supplement regimen.
Individual results may vary. The statements on this website have not been evaluated by the Food and Drug Administration. Products and information are not intended to diagnose, treat, cure, or prevent any disease.